TMC5 Modulation for Reversible Non-Hormonal Spermatogenesis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The etiology of non-obstructive azoospermia (NOA) remains largely unknown, with no recurrently mutated genes identified, posing a challenge for male infertility treatment and contraceptive development.
Innovation Solution
Targeting the transmembrane channel-like (TMC) protein family, particularly TMC5, through downregulation or upregulation of gene expression, using small molecules or RNA interference to modulate fertility, and developing diagnostic methods to quantify TMC5 expression in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional methods are used to treat male infertility, then treatment options are limited, but the complexity of identifying genetic causes increases
Solution Approach 1:
The patent changes the parameter of gene expression regulation by targeting TMC5 protein levels. By modulating TMC5 expression (downregulating for contraception, upregulating for infertility treatment), the invention provides versatile treatment options without requiring complex genetic sequencing or monogenic identification, thus resolving the contradiction between treatment adaptability and analysis complexity
Solution Approach 2:
The patent uses TMC5 protein as an intermediary target between the complex genetic causes of infertility and the desired therapeutic outcome. Instead of directly addressing unknown genetic etiology or requiring complex genomic analysis, the invention intermediates through TMC5 protein regulation to achieve both contraceptive and therapeutic effects, simplifying the overall approach
2Ease of operation
If small molecules are used to modulate TMC5 activity, then fertility regulation becomes reversible and non-hormonal, but the development and testing complexity increases
Solution Approach 1:
The patent employs small molecules that modulate TMC5 protein activity by changing its functional parameters (channel blocking, dimerization inhibition, interaction inhibition). This approach enables reversible and non-hormonal fertility regulation through simple parameter modulation rather than complex hormonal pathways, achieving ease of operation while managing development complexity through targeted molecular mechanisms
Solution Approach 2:
The patent replaces the mechanical complexity of hormonal regulation systems with direct molecular modulation of TMC5 proteins by small molecules. This substitution eliminates the need for complex endocrine system manipulation while achieving comparable fertility control, thereby simplifying the operational aspect of fertility regulation
3Adaptability or versatility
If TMC5 expression is downregulated to cause infertility, then male contraceptives become viable, but the risk of off-target effects and safety concerns increases
Solution Approach 1:
The patent applies local quality by ensuring TMC5-specific targeting through structurally defined small molecules that interact precisely with TMC5 protein features. The inventions demonstrate selective binding to TMC5 channels, dimers, or interaction interfaces, conferring local specificity that minimizes off-target effects while maintaining contraceptive efficacy across different tissue contexts
Solution Approach 2:
The patent incorporates feedback mechanisms through diagnostic methods that quantify TMC5 expression levels in biological samples. By monitoring TMC5 expression as a biomarker, the system provides feedback to adjust dosing and timing of contraceptive administration, optimizing efficacy while minimizing off-target effects through data-driven control
Data Source
AI summary
A method and composition for modulating male fertility are disclosed, centered on the targeted alteration of transmembrane channel-like (TMC) protein function, activity, or gene expression. Small molecules or pharmaceutically acceptable salts or solvates thereof are provided to modulate the activity or expression of TMC proteins, such as TMC5, in testis tissue. The compositions may include TMC5 channel blockers, dimerization inhibitors, TMC5-CIB1 interaction inhibitors, or small interfering RNAs targeting TMC5 mRNA, optionally formulated with a pharmaceutically acceptable carrier and capable of crossing the blood-testis barrier. Methods of diagnosing male infertility are also provided, comprising quantitating TMC5 expression or activity and comparing to a standard to identify infertility. These approaches enable reversible, non-hormonal regulation of spermatogenesis and fertility, offering new therapeutic strategies for male contraception and infertility treatment.